NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
Published on December 30, 2024
its national network, the Company's ability to raise adequate capital to fund the Hope Therapeutics acquisitions, and the Company's ability